Elward David Crawford

Elward David Crawford's AcademicInfluence.com Rankings

Philosophy

#5070

World Rank

#7788

Historical Rank

Logic

#2411

World Rank

#3398

Historical Rank

philosophy Degrees

Elward David Crawford

Biology

#6767

World Rank

#9556

Historical Rank

Biochemistry

#892

World Rank

#1000

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Elward David Crawford's Degrees

Doctorate Medicine Harvard University
PhD Biochemistry Stanford University

Why Is Elward David Crawford Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Elward David Crawford's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (2004) (3631)
Mortality results from a randomized prostate-cancer screening trial. (2009) (2824)
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. (2004) (2473)
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2009) (2033)
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. (1989) (1439)
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. (2012) (1053)
Multiple loci identified in a genome-wide association study of prostate cancer (2008) (970)
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. (2011) (942)
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. (2009) (940)
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. (2006) (887)
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. (2012) (883)
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. (2005) (805)
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. (1999) (726)
Characterising the castration‐resistant prostate cancer population: a systematic review (2011) (601)
Intermittent versus continuous androgen deprivation in prostate cancer. (2013) (471)
Epidemiology of prostate cancer. (2003) (433)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (429)
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. (2011) (382)
Radical retropubic prostatectomy. (1983) (374)
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. (2006) (290)
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. (2007) (253)
Identification of a new prostate cancer susceptibility locus on chromosome 8q24 (2009) (245)
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. (2006) (228)
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. (2007) (216)
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. (2010) (206)
Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. (2016) (197)
Genome-wide association study identifies new prostate cancer susceptibility loci. (2011) (183)
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. (1993) (183)
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. (2009) (183)
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. (2009) (183)
Estrogens in the treatment of prostate cancer. (1995) (182)
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial (2004) (182)
A Prospective Study of Lycopene and Tomato Product Intake and Risk of Prostate Cancer (2006) (176)
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. (2015) (176)
Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. (2012) (175)
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. (2005) (174)
Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. (1996) (174)
Clinical staging of prostate cancer: a computer‐simulated study of transperineal prostate biopsy (2005) (173)
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations (2018) (172)
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. (2003) (167)
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. (2005) (166)
Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years (2017) (166)
Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. (1998) (165)
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. (1998) (165)
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. (1996) (164)
Comorbidity and mortality results from a randomized prostate cancer screening trial. (2011) (161)
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial (2008) (161)
Association of African-American ethnic background with survival in men with metastatic prostate cancer. (2001) (160)
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. (2009) (159)
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials (2017) (159)
A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer (2010) (150)
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. (2010) (150)
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (2022) (149)
Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. (1994) (149)
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. (2011) (147)
Urodynamic evaluation of incontinence in patients undergoing modified Campbell radical retropubic prostatectomy: a prospective study. (1984) (144)
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. (2011) (144)
Clinical‐Pathologic Correlation Between Transperineal Mapping Biopsies of the Prostate and Three‐Dimensional Reconstruction of Prostatectomy Specimens (2013) (144)
Antiandrogen withdrawal in castrate‐refractory prostate cancer (2008) (140)
The "nutcracker" phenomenon: an unusual cause for renal varicosities with hematuria. (1980) (139)
Comparison of perspectives on prostate cancer: analyses of survey data. (1997) (136)
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. (2020) (129)
Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening (2009) (129)
Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. (2006) (128)
Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. (1982) (128)
Current management of invasive and metastatic transitional cell carcinoma of the bladder. (1993) (125)
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. (2001) (124)
Serum Prostate-Specific Antigen Hemodilution Among Obese Men Undergoing Screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (2009) (120)
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917 (2011) (116)
Adverse events associated with hormonal therapy for prostate cancer. (2005) (113)
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. (2011) (108)
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility (2009) (107)
The effect of digital rectal examination on prostate-specific antigen levels. (1992) (106)
Impact of previous local treatment for prostate cancer on subsequent metastatic disease. (2002) (104)
Complications of radical cystectomy for carcinoma of the bladder. (1980) (104)
Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review (2009) (103)
Challenges and recommendations for early identification of metastatic disease in prostate cancer. (2014) (100)
Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. (1995) (99)
Efficiency of prostate‐specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age‐specific reference range as a cutoff for abnormal values (1999) (98)
Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry (2014) (97)
The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. (2014) (97)
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). (2012) (96)
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. (2014) (96)
Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. (1994) (94)
A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. (2003) (94)
Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. (1996) (91)
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. (2006) (90)
Androgen deprivation therapy: past, present and future (2012) (89)
Transurethral ultrasound-guided laser-induced prostatectomy: National Human Cooperative Study results. (1993) (88)
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. (2014) (88)
Variant in Sex Hormone-Binding Globulin Gene and the Risk of Prostate Cancer (2007) (87)
Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. (1995) (87)
The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma (2000) (86)
Ten-year survival in patients with metastatic prostate cancer. (2003) (84)
Serum selenium and risk of prostate cancer-a nested case-control study. (2007) (82)
Optimal hormonal therapy for advanced prostatic carcinoma. (1999) (79)
Factors contributing to the racial differences in prostate cancer mortality (2005) (77)
Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. (2005) (76)
Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2014) (76)
Endogenous sex hormones and the risk of prostate cancer: A prospective study (2007) (75)
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III study (2009) (75)
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). (2009) (74)
The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. (2011) (73)
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer (2007) (71)
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. (2008) (71)
MRI-ultrasound registration for targeted prostate biopsy (2009) (70)
Prostate‐specific antigen velocity and prostate cancer gleason grade and stage (2007) (69)
Complications of intravesical chemotherapy. (1992) (67)
Salvage cystectomy after irradiation failure. (1980) (67)
Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex (1995) (63)
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. (2017) (62)
Extended follow‐up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial (2018) (60)
Terazosin, doxazosin, and prazosin: current clinical experience. (2001) (60)
New and emerging agents for the treatment of castration-resistant prostate cancer. (2011) (59)
The effect of bicycle riding on serum prostate specific antigen levels. (1996) (59)
Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. (2016) (58)
A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III) (2019) (58)
PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? (2008) (58)
Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) (2012) (56)
Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (2012) (56)
Navigating the evolving therapeutic landscape in advanced prostate cancer. (2017) (55)
A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone‐refractory prostate cancer (2006) (55)
The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials (2018) (55)
Association between race and follow‐up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial (2013) (55)
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. (2014) (54)
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. (2008) (54)
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. (2010) (53)
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation (2016) (52)
Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. (2011) (51)
Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma (2006) (51)
Hormonal therapy in prostate cancer: historical approaches. (2004) (51)
Metastatic prostate cancer-does treatment of the primary tumor matter? (2006) (50)
Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection. (1998) (50)
Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer. (2007) (50)
Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. (2011) (50)
The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. (2002) (50)
Screening for prostate cancer: current recommendations. (2004) (50)
The utility of prostate‐specific antigen in the management of advanced prostate cancer (2013) (49)
Challenges in the management of prostate cancer. (1992) (49)
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. (2009) (48)
Screening for prostate cancer with PSA testing: current status and future directions. (2011) (48)
Targeted focal therapy for the management of organ confined prostate cancer. (2014) (47)
The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. (2004) (47)
Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study (2006) (46)
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. (1995) (44)
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. (2010) (43)
Phase 1 trial of oral bropirimine in superficial bladder cancer. (1992) (43)
Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia (2006) (43)
New biomarkers in prostate cancer. (2014) (42)
Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. (2004) (41)
A 3-D reconstruction algorithm for interpolation and extrapolation of planar cross sectional data (1995) (41)
Targeted focal therapy for prostate cancer: a review. (2009) (41)
Three‐Dimensional Sonography With Needle Tracking (2008) (40)
Factors associated with oxidative stress and cancer risk in the Breast and Prostate Cancer Cohort Consortium (2014) (40)
The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer (2006) (39)
Racial differences in serum prostate‐specific antigen (PSA) doubling time, histopathological variables and long‐term PSA recurrence between African‐American and white American men undergoing radical prostatectomy for clinically localized prostate cancer (2005) (39)
Dutasteride: A Review of its Use in the Management of Prostate Disorders (2011) (39)
UPDATE OF SWOG 8794: ADJUVANT RADIOTHERAPY FOR PT3 PROSTATE CANCER IMPROVES METASTASIS FREE SURVIVAL (2008) (38)
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. (2012) (38)
Genetic Variation in the Vitamin D Pathway in Relation to Risk of Prostate Cancer—Results from the Breast and Prostate Cancer Cohort Consortium (2013) (37)
Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial (2007) (36)
Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. (2001) (36)
Current genitourinary cancer surgery (1991) (36)
Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison. (2018) (36)
Adaptation of a 3D prostate cancer atlas for transrectal ultrasound guided target-specific biopsy (2008) (35)
Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. (1994) (35)
Current status of combined androgen blockade: optimal therapy for advanced prostate cancer. (1995) (35)
Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. (2006) (35)
Leuprorelin depot injection: patient considerations in the management of prostatic cancer (2008) (33)
The role of LHRH antagonists in the treatment of prostate cancer. (2009) (33)
The Current Use and Future Trends of Focal Surgical Therapy in the Management of Localized Prostate Cancer (2007) (33)
The role of prostate‐specific antigen in the chemoprevention of prostate cancer (1996) (33)
Large-scale fine mapping of the HNF1B locus and prostate cancer risk. (2011) (33)
Total androgen ablation: American experience. (1991) (33)
Prostate specific antigen density in patients with histologically proven prostate carcinoma (1994) (32)
Combined androgen blockade: the gold standard for metastatic prostate cancer. (1997) (31)
Prostate Cancer Awareness Week, 1992: a summary of key findings. (1993) (31)
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). (2017) (30)
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials (2013) (30)
Castration-resistant prostate cancer: descriptive yet pejorative? (2010) (30)
Management of regional lymphatic drainage in carcinoma of the penis. (1992) (30)
Preoperative radiation therapy in the treatment of bladder cancer. (1987) (30)
Traditional androgen ablation approaches to advanced prostate cancer: new insights. (2014) (29)
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. (2018) (29)
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. (2003) (29)
High-intensity focused ultrasound: ready for primetime. (2010) (29)
ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. (2015) (29)
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines (2020) (29)
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. (2006) (28)
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. (2007) (28)
Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer. (2003) (28)
Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. (2012) (28)
Clinical staging of prostate cancer: Reproducibility and clarification of issues (2001) (27)
Image Registration Accuracy of a 3‐Dimensional Transrectal Ultrasound–Guided Prostate Biopsy System (2009) (26)
Metastatic cancer in solid tumors and clinical outcome: skeletal-related events. (2009) (26)
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. (2010) (26)
Controversies regarding screening for prostate cancer (2007) (24)
Insulin‐like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) (2013) (24)
Role of testosterone in managing advanced prostate cancer. (2012) (24)
Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2 (2010) (24)
Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy. (2000) (24)
The management of high risk prostate cancer. (2003) (23)
Focal therapy in prostate cancer: future trends (2005) (23)
Intermittent androgen deprivation therapy: redefining the standard of care? (2010) (23)
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. (2018) (23)
Prostate cancer awareness week. Education, service, and research in a community setting (1995) (23)
Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl (2015) (22)
The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. (1994) (22)
The PCPT: New Findings, New Insights, and Clinical Implications for the Prevention of Prostate Cancer (2006) (22)
Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. (1993) (22)
Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of Phytotherapy for Benign Prostatic Hyperplasia (2009) (22)
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men (2021) (22)
Combined androgen blockade (1989) (21)
Chemoprevention of prostate cancer: Guidelines for possible intervention strategies (1992) (21)
Current status of combined androgen blockade: optimal therapy for advanced prostate cancer [published erratum appears in J Clin Endocrinol Metab 1995 Jul;80(7):2056] (1995) (20)
Controversies : Endocrine therapy of prostate cancer : optimal form and appropriate timing (1995) (20)
Treatment of advanced seminoma with pre-radiation chemotherapy. (1983) (20)
Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer. (2008) (20)
Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatc hyperplasia (1993) (20)
The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. (2013) (20)
Controversies in the treatment of metastatic prostate cancer (1992) (20)
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility (2017) (19)
Combined low‐dose flutamide plus finasteride vs low‐dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long‐term follow‐up (2009) (19)
Hormonal pretreatment does not affect the final pathologic stage in locally advanced prostate cancer (1994) (18)
Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. (2011) (18)
The Role of the FSH System in the Development and Progression of Prostate Cancer (2014) (18)
Maximal testosterone suppression in prostate cancer--free vs total testosterone. (2014) (18)
Effect of Statins on Serum Prostate-specific Antigen Levels. (2010) (18)
Laterally directed biopsies detect more clinically threatening prostate cancer: Computer simulated results (2003) (17)
Proliferative Tumor Doubling Times of Prostatic Carcinoma (2011) (17)
RESPONSE: Re: Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer (2001) (17)
Minimally Invasive Surgery in Prostate Cancer: Current and Future Perspectives (2005) (17)
ANDROGEN DEPRIVATION THERAPY USING FINASTERIDE AND LOW DOSE FLUTAMIDE TO TREAT PSA FAILURE FOLLOWING THERAPY FOR CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE (CaP) (1999) (16)
Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer (2017) (16)
Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks. (2003) (16)
Preventing and treating the complications of hormone therapy (2005) (16)
Psychosocial counseling of cancer patients by telephone: A brief note on patient acceptance of an outcall strategy (1993) (16)
The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. (2019) (15)
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia : SWOG S 9917 (2011) (15)
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. (2012) (15)
An opportunity to determine optimal treatment of pT3 prostate cancer: the window may be closing. (1994) (15)
Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects (2018) (15)
Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP (2014) (15)
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. (2016) (14)
A randomized controlled clinical trial of leuprolide and anandron versus leuprolide and placebo for advanced prostate cancer (1990) (14)
Prostate cancer pathology, screening, and epidemiology. (2001) (14)
The use of flutamide as a single antiandrogen treatment for hormone‐refractory prostate cancer (2003) (14)
Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. (1993) (14)
Genitourinary malignancies. (2005) (14)
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist (2018) (14)
Should routine screening for prostate-specific antigen be recommended? (2003) (14)
Diagnosis and management of local recurrence after low-dose-rate brachytherapy. (2015) (13)
Hormone refractory prostate cancer. (1999) (13)
1665: Adjuvant Radiotherapy for Pathologic T3 Prostate Cancer: Results of a Randomized, Prospective Clinical Trial with Metastasis-Free Survival Endpoint (2005) (13)
Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models. (2004) (13)
Diagnosis and treatment of superficial bladder cancer: an update. (1996) (13)
Hormone therapy of advanced prostate cancer: where we stand today. (1991) (13)
Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. (2021) (12)
Prostate Cancer Awareness Week: September 22 to 28, 1997 (1997) (12)
Minimal toxicity with 3-FAT radiotherapy of prostate cancer. (2000) (12)
The Accuracy of Prostate Cancer Localization Diagnosed on Transrectal Ultrasound-Guided Biopsy Compared to 3-Dimensional Transperineal Approach (2013) (12)
The role of FSH and LH in prostate cancer and cardiometabolic comorbidities. (2020) (12)
Measurement of testosterone: how important is a morning blood draw? (2015) (12)
Methods of developing UWIN, the modified American Urological Association symptom score. (2011) (12)
Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. (2017) (12)
Genitourinary cancer surgery (1982) (12)
Urodynamic features of pelvic plexus injury. (1980) (12)
Anterior tumors of the prostate: diagnosis and significance. (2013) (12)
Early versus late hormonal therapy: debating the issues. (2003) (12)
Treatment of localized prostate cancer. (2006) (12)
Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: The results from IMAAGEN core study. (2014) (11)
Targeted focal therapy for prostate cancer: a review of the literature (2009) (11)
Controversies of androgen ablation therapy for metastatic prostate cancer. (2006) (11)
Testosterone and the prostate: Implications for the treatment of hypogonadal men (2008) (11)
Validation of the modified American Urological Association symptom score. (2011) (11)
Intercostal nerve block with thoracoabdominal and flank incisions (1982) (11)
The role of the urologist in treating patients with hormone-refractory prostate cancer. (2003) (11)
PSA as a screening test for prostate cancer. (1993) (11)
Pelvic lipomatosis: diagnosis by computerized tomography scan. (1978) (11)
Transperineal percutaneous iridium-192 implant of the prostate. (1983) (11)
Proposed substages for metastatic prostate cancer. (1997) (11)
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. (2015) (11)
Prostate cancer: epidemiology and screening. (2000) (11)
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. (2006) (11)
Management of asymptomatic rising PSA after prostatectomy or radiation therapy. (1997) (10)
Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer (2020) (10)
Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime. (1992) (10)
IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer. (2016) (10)
Benign prostatic disease. A growing challenge in the 1990s. (1993) (10)
Priapism secondary to prazosin overdose. (1983) (10)
Effects of Testosterone Level on Lower Urinary Tract Symptoms (2016) (10)
Chemoprevention strategies in the prostate: an overview. (2002) (10)
Maximal androgen withdrawal for prostate cancer therapy: current status and future potential (1998) (10)
Southwest Oncology Group strategies in prostatic carcinoma. (1995) (10)
Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916 (2008) (10)
A Comparison of Leuprolide with Flutamide and Leuprolide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate, Phase III, Intergroup Study-0036 (1987) (9)
A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG) (2008) (9)
Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. (2017) (9)
Multi-parametric MRI findings of transitional zone prostate cancers: correlation with 3-dimensional transperineal mapping biopsy (2014) (9)
Late development of a urethrocavernous fistula after cavernospongiosum shunt for priapism. (1984) (9)
Incomplete testosterone suppression in prostate cancer. (2010) (9)
Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts (2012) (9)
P109 Efficacy and safety of a 3-monthly depot formulation of degarelix compared with goserelin in prostate cancer (2012) (9)
670 SWITCHING FROM LEUPROLIDE TO DEGARELIX VS CONTINUOUS DEGARELIX TREATMENT – EFFECTS ON LONG-TERM PROSTATE-SPECIFIC ANTIGEN CONTROL (2010) (9)
Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer (2013) (9)
Diagnosis and management of prostate cancer. (1986) (9)
ARTIFICIAL INTELLIGENCE SYSTEM IN PREDICTION OF LYMPH NODE INVOLVEMENT IN RADICAL PROSTATECTOMY PATIENTS (1999) (8)
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? (2005) (8)
The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. (2007) (8)
Rapid increase in calculous size: a possible hazard of phenazopyridine hydrochloride therapy in the presence of already formed stones. (1978) (8)
12-WEEK RESULTS OF A PHASE II TRIAL OF 100 AND 300 UNITS BOTULINUM NEUROTOXIN TYPE A (BONT-A) FOR THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) (2009) (8)
Dissolution of vesical calculi with renacidin in a paraplegic man (1980) (8)
Re: salvage cystectomy for bladder cancer after failure of definitive irradiation. (1982) (8)
Avoiding obsolescence in advanced prostate cancer management: a guide for urologists (2015) (8)
The Utility of Prostate-Specific Antigen as a Surrogate Marker for Identification of High-Risk Cohorts and Assessing Response in Chemoprevention Trials (1999) (8)
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data (2020) (8)
Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial. (2015) (8)
The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. (1994) (8)
Screening for prostate cancer. (2004) (7)
Urologists' attitudes regarding cancer clinical research. (2007) (7)
Lymphomatoid tumor infiltration of renal veins. (1979) (7)
Giant dendritic struvite calculus associated with transitional cell carcinoma of the ipsilateral renal pelvis and bladder: a case report and review of the literature. (1979) (7)
Co-existent renal eosinophilic granuloma and renal adenocarcinoma (1980) (7)
High-intensity Ultrasound: Ready for Primetime (2010) (7)
Sarcoidosis in a man with renal carcinoid tumor. (2007) (7)
IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer. (2015) (7)
Screening for prostate cancer in 2006: PSA in the 21st century. (2006) (7)
Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate. (1992) (7)
Combined androgen blockade. (1989) (6)
Renal cell carcinoma in a horseshoe kidney associated with von Hippel-Lindau disease. (1979) (6)
Diagnosis and treatment of prostatitis. (1985) (6)
National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo. (1991) (6)
To screen or not to screen: the prostate cancer dilemma (2014) (6)
Southwest Oncology Group studies in hormone-refractory prostate cancer. (1996) (6)
Base of the skull metastases in metastatic castration-resistant prostate cancer. (2014) (6)
716 ANALYSIS OF DISEASE CONTROL-RELATED OUTCOMES FROM SIX COMPARATIVE RANDOMISED CLINICAL TRIALS OF DEGARELIX VERSUS LUTEINISING HORMONE-RELEASING HORMONE AGONISTS (2013) (6)
Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy (2017) (6)
Therapeutic strategies for localized prostate cancer. (2001) (6)
Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer. (2011) (6)
Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. (1996) (6)
The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. (2006) (6)
Renal arteriovenous fistulas secondary to bilateral renal cell carcinoma. (1979) (6)
A review of the use of histrelin acetate in the treatment of prostate cancer (2009) (6)
Androgen deprivation and other treatments for advanced prostate cancer. (2001) (6)
Renal mass in man with eosinophilic granuloma. (1980) (5)
Advanced prostate cancer: an update. (2000) (5)
Transrectal ultrasound-guided prostate biopsy : current approach (2010) (5)
Ultrasonic detection of renal tubular carcinoma extending into the inferior vena cava. (1980) (5)
Lack of Low-risk Pathologic Findings in SWOG 8794 (2009) (5)
Prostatic comedocarcinoma: correlation of sonograms with pathologic specimens in three cases. (1990) (5)
Pretreatment of metastatic disease. Prostate cancer in the older male. (1994) (5)
Deep venous thrombosis following transurethral resection of the prostate: diagnosis by phleborheography. (1978) (5)
Intermediate- to high-risk prostate cancer patient treated with radiation therapy. (2004) (5)
Is a screening interval of every 4 years for prostate cancer acceptable? (2007) (5)
Low‐grade prostate cancer should still be labelled cancer (2022) (5)
Prostate cancer clinical trials of the Southwest Oncology Group. (1997) (5)
Nephrogenic adenoma associated with interstitial cystitis. (1985) (5)
Human feasibility study of fluorescence spectroscopy guided optical biopsy needle for prostate cancer diagnosis (2015) (4)
532: Distribution of Gleason Scores Among Men Discovered to Have Prostate Cancer (CAP) in the Medical Therapy of Prostatic Symptoms (MTOPS) Trial (2005) (4)
THE ROLE OF THREE DIMENSIONAL SYSTEMATIC MAPPING BIOPSY OF THE PROSTATE IN MEN PRESENTING WITH APPARENT LOW RISK DISEASE BASED ON EXTENDED TRANSRECTAL BIOPSY (2008) (4)
Intercostal nerve block with thoracoabdominal and flank incisions Urology, 19 (1982) 25–28 (1982) (4)
The Role of FSH in Prostate Cancer: A Case Report (2016) (4)
Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. (2015) (4)
Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. (2022) (4)
Summary: the role of the urologist in chemotherapy of hormone refractory prostate cancer. (1999) (4)
Evaluation of the economic impact of the CCP assay in localized prostate cancer. (2015) (4)
Complementary medicine, chemoprevention, and staging of prostate cancer. (2003) (4)
The 3DBiopsy Prostate Biopsy System: Preclinical Investigation of a Needle, Actuator, and Specimen Collection Device Allowing Sampling of Individualized Prostate Lengths Between 20 and 60 mm. (2017) (4)
Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo. (1990) (4)
Cryosurgical ablation of the prostate: the con side in 1996. (1996) (4)
Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer (2018) (4)
Evaluation of the 29 MHz Micro-Ultrasound Imaging for Prostate Cancer Diagnosis and Treatment (2019) (4)
Vena cava tumor thrombus from renal cell carcinoma arising from adrenal vein. (1984) (4)
Intercostal nerve block with thoracoabdominal incision. (1979) (4)
1324: Diurnal Serum Testosterone Variation in Aging Men: Cross-Sectional Analysis from a Large National Screening Program Reveals Only a Modest Decline Beginning in the Mid-Afternoon (2006) (4)
CCP score and risk stratification for prostate cancer patients at biopsy. (2014) (4)
678 Disease control-related outcomes from an analysis of six comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone (LHRH) agonists (2013) (4)
3D Biopsy: A New Method to Diagnose Prostate Cancer (2016) (4)
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. (2020) (4)
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential. (2019) (3)
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer : Results of a randomized, double-blind, placebo-controlled clinical trial. Commentary (1998) (3)
New Markers for Prostate Cancer Detection and Prognosis (2016) (3)
161 DETERMINATION OF CLINICAL CHARACTERISTICS FOR MEN ON ADT AS RELATED TO BASELINE SERUM TESTOSTERONE VALUES (2011) (3)
The Prostate Cancer Dilemma (2016) (3)
The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer (2018) (3)
Radical ilioinguinal lymphadenectomy. (1984) (3)
Three Different Strategies for Real-Time Prostate Capsule Volume Computation from 3-D End-Fire Transrectal Ultrasound (2007) (3)
Prostate cancer. Introduction. (2003) (3)
Original Articles: Bladder Cancer (1995) (3)
Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer (2009) (3)
DOES BMI IMPACT PSA CONCENTRATION BY VARIATION IN PLASMA VOLUME (2008) (3)
1780 MIST2: BASELINE PSA AND TOTAL PROSTATE VOLUME PREDICTS CLINICAL RESPONSE TO INTRAPROSTATIC INJECTION OF BOTULINUM TOXIN FOR THE MANAGEMENT OF LUTS (2010) (3)
A young woman with multiple kidney lesions. (2010) (3)
Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated? (2005) (3)
Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894 (2004) (3)
Systematic diagnosis of prostate cancer using an optical biopsy needle adjunct with fluorescence spectroscopy (2014) (3)
866 PROSTATE-SPECIFIC ANTIGEN AND SERUM ALKALINE PHOSPHATASE LEVELS IN PROSTATE CANCER PATIENTS RECEIVING DEGARELIX OR LEUPROLIDE (2010) (3)
MP73-12 UNSUSPECTED METASTASES FOUND DURING SCREENING FOR A TRIAL OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER (2015) (3)
1455: Immediate VS Delayed Hormonal Therapy (HT) in Patients with Nodal Positive (N+) Prostate Cancer Who Had Undergone Radical Prostatectomy (RP) + Pelvic Lymphadenectomy (LND): Results of Central Pathology Review (CPR) (2004) (3)
"PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older. (2020) (3)
Chapter 18 – Artificial Neural Networks for Predictive Modeling in Prostate Cancer (2003) (2)
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent. (2020) (2)
Retrocrural lymphadenopathy in testicular cancer. (1984) (2)
Bone metabolism and new targets for intervention (2007) (2)
N12 SWITCHING FROM LEUPROLIDE TO DEGARELIX VS. CONTINUOUS DEGARELIX TREATMENT – EFFECTS ON LONG-TERM PSA CONTROL (2010) (2)
Finding Occult Prostatic Cancer: The Value of Transperineal Mapping Biopsies and Epigenetic Assays (2014) (2)
MP53-13 DIAGNOSIS OF HIGH GRADE PROSTATIC CANCER USING DIFFUSE REFLECTANCE SPECTROSCOPY (2014) (2)
The effect of cell cycle progression (CCP) score on treatment decisions in prostate cancer: Results of an ongoing registry trial. (2014) (2)
PCA3: A urine-based genetic assay for detection of prostate cancer in men with elevated PSA. (2010) (2)
THE ROLE OF 3D MAPPING BIOPSY OF THE PROSTATE IN DECISION MAKING FOR TREATMENT OF EARLY STAGE PROSTATE CANCER (2009) (2)
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. (1995) (2)
Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer. (2021) (2)
PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer (2009) (2)
196 TRANSPERINEAL MAPPING BIOPSIES PROVIDE IMPROVED HISTOPATHOLOGICAL CORRELATION WITH WHOLE-MOUNTED PROSTATECTOMY SPECIMENS (2011) (2)
Dutasteride: novel milestones in prostate cancer chemoprevention. (2011) (2)
Flank pain and microhematuria in a young woman. (1980) (2)
Rising PSA After Local Therapy Failure: Immediate vs Deferred Treatment (1999) (2)
Target focal therapy in early prostate cancer: Initial single institution results (2007) (2)
First International Conference on Chemoprevention of Prostate Cancer (2004) (2)
Intermittent Androgen Deprivation with the GnRH Antagonist Degarelix in Men with Biochemical Relapse of Prostate Cancer (2015) (2)
Individual, DNA-guided, antibacterial prophylaxis prior to transrectal prostate biopsy based on results of next generation sequencing (NGS) of rectal swabs can be considered as a promising targeted approach to prevent severe urinary tract infection (2019) (2)
Ceftizoxime in the treatment of urinary tract infections. (1982) (2)
PROSTATE VOLUME REDUCTION WITH DUTASTERIDE PRIOR TO MAPPING BIOPSIES (2009) (2)
A Clinician's Guide to Targeted Precision Imaging in Patients With Prostate Cancer (RADAR VI) (2022) (2)
Are They Helpful to Policy Makers? (2006) (2)
Bidirectional segmentation of prostate capsule from ultrasound volumes: an improved strategy (2008) (2)
1723 USE OF A 1.5 PSA THRESHOLD TO IDENTIFY INCREASED RISK FOR PROSTATE CANCER IN A SCREENING POPULATION (2010) (2)
A comparison of leuprolide with flutamide and leuprolide in previously untreated patients with clinical stage D2 (1987) (2)
Prostate cancer awareness: Much has changed since '89 (2005) (1)
Inguinal lymph node metastases following a Torek orchiopexy. (1983) (1)
Completely automated estimation of prostate volume for 3-D side-fire transrectal ultrasound using shape prior approach (2008) (1)
Monotherapy versus combined androgen blockade in patients with advanced prostate cancer (2002) (1)
PD32-11 SIGNIFICANT REDUCTION IN THERAPEUTIC BURDEN FROM USE OF CCP TEST IN TREATMENT DECISIONS AMONG NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A LARGE PROSPECTIVE REGISTRY (2015) (1)
Re: Calculi Complicating Intermittent Catheterization, by M. Hugh Solomon, Stephen A. Koff and Ananais C. Diokno, J. Urol., 124: 140–141, 1980 (1981) (1)
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. (2004) (1)
1693: Segmentation of Trus Prostate Images for 3-Dimentional Biopsy Applications (2007) (1)
Reply to Rune Kvåle, Eivor Hernes and Freddie Bray's Letter to the Editor re: E. David Crawford, Per-Anders Abrahamsson. PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests? Eur Urol 2008;54:262–73 (2009) (1)
Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment. (2010) (1)
Routine screening for cancer of the prostate. (1991) (1)
CLO22-049: Major Adverse Cardiovascular Events Risk After Androgen Deprivation Therapy Initiation is Higher for Older Patients (2022) (1)
Therapeutic strategies for localized prostate cancer I: surgery, ultrasound, adjuvant and neoadjuvant therapy. (2000) (1)
Surgical management of prostate cancer: optimizing patient selections and clinical outcome. (2005) (1)
MP40-06 ASSESSING THE ABILITY OF THE MALE ANDROGEN DEFICIENCY SYNDROME (MADS) SCREENING QUESTIONNAIRE TO PREDICT HYPOGONADISM (2019) (1)
Small steps that lead to a giant leap for prostate cancer patients. (2014) (1)
MP6-06 PROSTATE HEALTH INDEX PREDICTS UPGRADING OF MEN ON 5-ALPHA REDUCTASE INHIBITORS (2015) (1)
1629 TOTAL TESTOSTERONE NOT ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS IN A PROSTATE CANCER SCREENING POPULATION (2010) (1)
Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894. (2004) (1)
New instrument for placement of circle tube nephrostomy. (1980) (1)
CRYOABLATION OF THE PROSTATE. AUTHORS' REPLY (1995) (1)
THE UTILITY OF ULTRASOUND DERIVED PROSTATE PARAMETERS IN PREDICTING CLINICAL RESPONSE IN MEN TREATED WITH BOTULINUM NEUROTOXIN TYPE A (BONT-A) FOR BENIGN PROSTATIC HYPERPLASIA (BPH) (2009) (1)
Metagenomic next generation sequencing analysis of vaginal microbiome composition in patients with bacterial vaginosis treated with lactin-v (Lactobacillus crispatus CTV-05) versus placebo (2020) (1)
Prostate Cancer Academy 2016: Presentation summaries. (2016) (1)
PRE-BIOPSY PROSTATE CANCER NOMOGRAMS BASED UPON SERIAL PSA SCREENING DATA IN THE PLCO TRIAL WITH VERIFICATION BIAS CORRECTION (2009) (1)
993 FACTORS INFLUENCING INITIAL TREATMENT DECISIONS IN PLCO: COMPARISON OF SCREENING AND CONTROL ARMS (2012) (1)
SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer. (2019) (1)
Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer. (2010) (1)
333 FAMILY HISTORY OF VARIOUS CANCERS AND THE RISK OF INCIDENT PROSTATE CANCER IN THE PLCO TRIAL (2011) (1)
960 OPTIMAL TIMING FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): SEQUENCING AND IDENTIFYING PARAMETERS OF EARLY PROGRESSION WITH SIPULEUCEL-T (2013) (1)
Advanced prostate cancer: therapeutic sequencing, outcomes, and cost implications. (2012) (1)
Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma (2016) (1)
Prostatitis and Urethritis (1999) (1)
ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC). (2017) (1)
Type III statistical error. (1998) (1)
Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial (2021) (1)
ARTIFICIAL NEURAL NETWORK ANALYSIS (ANNA) OF SUBVISUAL TRANSRECTAL ULTRASOUND INFORMATION: THREE DIMENSIONAL PROSTATE CANCER DIAGNOSIS AND STAGING (1999) (1)
Rebuttal by Drs Oottamasathien and Crawford (2003) (1)
Effect of gonadotrophin-releasing hormone antagonist induced follicle-stimulating hormone suppression on prostate-specific antigen response (2017) (1)
Synthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII) (2023) (1)
720 TIME TO PROGRESSION IN PATIENTS WITH PROSTATE CANCER: A COMPARISON OF CONTINUOUS DEGARELIX VERSUS DEGARELIX FOLLOWING LEUPROLIDE TREATMENT (2011) (1)
Short- and long-term genitourinary symptom status and global quality of life (QOL) from a Southwest Oncology Group (SWOG) Trial (2005) (1)
Clinical Considerations after a Negative Prostate Biopsy (2016) (1)
MEDICAL THERAPY USE AMONG MEN AT INCREASED RISK OF BPH PROGRESSION BASED ON THE PSA THRESHOLD OF 1.5 NG/ML OR GREATER: AN ANALYSIS OF DATA FROM THE PROSTATE CANCER AWARENESS WEEK SCREENING PROGRAM (2009) (1)
MP18-15 EFFICACY OF HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) AS A PRIMARY MONOTHERAPY FOR LOW RISK LOCALIZED PROSTATE CANCER: OUTCOMES FROM THE ENLIGHT TRIAL (2011) (1)
477: Body Mass Index and Impact on PSA Screening and Prostate Cancer Detection in the Plco Trial (2006) (1)
Woman with a papillary pulmonary lesion and a complex renal cyst. (2006) (1)
The Role of Hormonal Therapy in the Treatment of Locally Advanced Prostate Cancer—Regional Perspectives: USA (2004) (1)
Prostate-specific antigen in screening for prostate cancer. (1994) (1)
1556: Phase 1 Dose Escalation Clinical Trial of Intrprostatic Injection of Botulinum Toxin Type a in Men with Obstructive LUTS Due to Benign Prostatic Hyperplasia (2007) (1)
Racial variation in follow-through of a positive screening test for prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (2011) (1)
Experience of Prostate Cancer Awareness Week (2001) (1)
535: Relationships of Life Style with PSA, Testosterone and Cholesterol in a Large Cohort of Men Screened or Prostate Cancer (2006) (1)
Assessment of men before androgen deprivation therapy. (2011) (0)
3T MRI of the prostate correlation to 3D reconstruction of transperineal mapping biopsies. (2012) (0)
Rising PSA level in a 46-year-old man. (2013) (0)
Reply by Authors. (2019) (0)
Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove. (2006) (0)
16TH INTERNATIONAL PROSTATE CANCER UPDATE Treatment of Localized Prostate Cancer (2006) (0)
POTENTIAL FOR INCREASE IN SCREENING INTERVAL BASED ON INITIAL PSA: DATA FROM THE PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL (2009) (0)
INITIAL PSA LEVELS AND PROSTATE CANCER DIAGNOSIS WITH UP TO 7 YEARS FOLLOW-UP IN THE PLCO CANCER SCREENING TRIAL (2009) (0)
Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men (2009) (0)
EDITORIAL COMMENT. (2020) (0)
Serum alkaline phosphatase levels in men with prostate cancer treated with a gonadotropin-releasing hormone agonist or antagonist (2015) (0)
Identification of the index lesion and contralateral significant cancer in men undergoing transperineal mapping biopsy (2019) (0)
BJUI awards three ‘Best Paper’ prizes. (2012) (0)
1440: Association of Stromal, Epithelial, Smooth Muscle, and Luminal Compositions to Nodule Size and Symptom Severity of Benign Prostatic Hyperplasia (2006) (0)
3-D statistical cancer atlas-based targeting of prostate biopsy using ultrasound image guidance (2008) (0)
Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men. (2009) (0)
Combination studies with leuprolide. (1990) (0)
MP20-02 ACCURACY OF MPMRI IN IDENTIFYING CLINICALLY SIGNIFICANT PROSTATE CANCER BY QUADRANT WHEN COMPARED TO TRANSPERINEAL MAPPING BIOPSY (2020) (0)
LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL (2022) (0)
The Challenge of Comparing Investigative Approaches to Prostate Cancer (2008) (0)
PCA3: A urine-based genetic assay for detection of prostate cancer in men with elevated PSA (2009) (0)
Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma. (1988) (0)
Laparoscopic procedures in urologic oncology (1996) (0)
FREE AND TOTAL PSA IN 7,183 PILOT STUDY PARTICIPANTS IN THE PLCO SCREENING TRIAL (1999) (0)
838TiPARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC) (2017) (0)
Application of active surveillance threshold to series of samples submitted for commercial testing. (2016) (0)
V4-09 TRANSPERINEAL PROSTATE BIOPSY WITH NEW MAPPING SOFTWARE (2015) (0)
1883: Outcomes of Men with Initial Elevated PSA Over Three Subsequent Annual Screening Rounds in PLCO (2007) (0)
1509: Factors Responsible for Failure to Recruit in a Clinical Trial Comparing Minimally Invasive Surgical Therapy with Combination Drug Treatment for Benign Prostatic Hyperplasia (2006) (0)
Prostate Cancer : A Review of Current Prostate Cancer Markers and a Novel Model of Organization CONTENTS 1 Prostate Cancer : A Review of Current Prostate Cancer Markers and a Novel Model of Organization (2017) (0)
EFFECT OF OBESITY AT AGE 20 AND 50 ON DEVELOPMENT OF PROSTATE CANCER IN THE PLCO CANCER SCREENING TRIAL (2009) (0)
Real-world analyses of major adverse cardiovascular event risk by drug class after initiation of androgen deprivation therapy. (2022) (0)
Abstract #5613: Functional analysis of the promoter of the beta-microseminoprotein gene MSMB demonstrates the importance of a single nucleotide polymorphism in prostate cancer susceptibility (2009) (0)
Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer (2016) (0)
13TH INTERNATIONAL PROSTATE CANCER UPDATE (2003) (0)
Prostate cancer: defining the challenges (1993) (0)
2042 PROSTATE CANCER AND MEN'S HEALTH SCREENING: COMPARISON OF THE SCREENING POPULATIONS FROM 2003 AND 2009 (2011) (0)
Editorial Comment. (2021) (0)
Adult Urology Urologists' Attitudes Regarding Cancer Clinical Research (2007) (0)
PROSTATE CANCER RISK AND INITIAL TREATMENT DECISIONS IN THE PLCO CANCER SCREENING TRIAL (2008) (0)
Biphenotypic extramedullary blast crisis of chronic myeloid leukemia with variant Philadelphia chromosome translocation. (2015) (0)
MP23-09 COMPARISON OF POSTOPERATIVE CATHETER-ASSOCIATED URINARY TRACT INFECTION (CAUTI) RATES IN THE UROLOGIC PATIENT WITH A SUPRAPUBIC CATHETER VERSUS TRANSURETHRAL CATHETER (2018) (0)
Editorial Comment. (2022) (0)
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. (1995) (0)
Landmarks in hormonal therapy for prostate cancer (2013) (0)
MP13-06 MULTICENTER CLINICAL TRIAL OF REAL-TIME PROSTATE CANCER DIAGNOSIS USING OPTICAL SPECTROSCOPY GUIDED PROSTATE BIOPSY (2019) (0)
Application of statistical cancer atlas for 3D biopsy (2008) (0)
Androgen D eprivation a nd F our C ourses o f F ixed-Schedule Suramin T reatment i n P atients W ith N ewly D iagnosed Metastatic P rostate C ancer: A S outhwest O ncology Group S tudy (2000) (0)
575: Proliferative Tumor Doubling Times of Prostatic Carcinoma Measured by in Vivo Bromodeoxyuridine (BRDU) Labeling and Flow Cytometric Analysis (2005) (0)
PD10-10 IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (2020) (0)
Proton Beam Therapy Utilization and Disparity in the United States for Treatment of Localized Prostate Cancer: A Study of the National Cancer Data Base (2016) (0)
Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer. (2022) (0)
Editorial Comments: Combination Finasteride and Flutamide in Advanced Carcinoma of the Prostate (1995) (0)
Commentary (Crawford): Morbidity of Contemporary Radical Retropubic Prostatectomy for Localized Prostate Cancer (1995) (0)
The Prostate AStudyofHigh-DoseOral Silybin-Phytosome Followedby Prostatectomyin PatientsWith Localized ProstateCancer (2010) (0)
Commentary (Crawford): Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer (2002) (0)
Magnetic Resonance Spectroscopy (MRS) of Prostatic Fluids for Early Detection of Prostate Cancer (2006) (0)
Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data. (2020) (0)
Risk Assessment and Diagnosis Effect of Statins on Serum Prostate-specific Antigen Levels (2010) (0)
Recent advances in hormonal therapy for advanced prostate cancer. (2003) (0)
Bone metabolism and new targets for intervention (2007) (0)
522: Relationship of PSA Velocity and Gleason Score in the PLCO Cancer Screening Trial (2006) (0)
PD26-12 COMPLICATIONS ASSOCIATED WITH TRANSRECTAL AND TRANSPERINEAL PROSTATE MAPPING BIOPSY (2016) (0)
PATTERN OF PROSTATE-SPECIFIC ANTIGEN CHANGE IN 3 YEARS IN MEN WITH INITIAL NORMAL SCREENING TESTS (1999) (0)
1721: The Observed Correlation between Testosterone Levels and Prostate Specific Antigen Values in a Large Screening Population (2007) (0)
Management of Advanced/Metastatic Prostate Cancer: 2000 Update (2017) (0)
Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients. (2015) (0)
A REDUCED AMERICAN UROLOGICAL ASSOCIATION SYMPTOM SCORE (2009) (0)
Clinical Investigation : Genitourinary Cancer The Impact of Definitive Local Therapy for Lymph Node e Positive Prostate Cancer : A Population-Based Study (2014) (0)
1285: The Correlation between Luts (AUA-SS) and Erectile Dysfunction (SHIM) in an Age Matched Racially Diverse Male Population: Data from the Prostate Cancer Awareness Week (PCAW) (2005) (0)
Editorial Comment: Intraversical Recombinant Tumor Necrosis Factor in the Treatment of Superficial Bladder Cancer (1995) (0)
Is there a Role for Targeted Focal Therapy of Prostate Cancer (2012) (0)
A 42-year-old woman with breast cancer. (2003) (0)
ClariCore™ Optical Biopsy System for Prostate Cancer Diagnosis: Preliminary Results from a Multicenter Clinical Trial (2017) (0)
Should hormone treatment be started early in response to rising prostate-specific-antigen levels? (2007) (0)
Abstract 3863: Fine mapping and comprehensive resequencing analysis of a region of chromosome 11q13 reveals multiple independent loci associated with prostate cancer (2010) (0)
45 PREVALENCE AND PREDICTORS OF SUPPLEMENT USE IN A POPULATION OF ADULT MEN: A POTENTIAL CONCERN (2010) (0)
PD2-04 TESTOSTERONE REPLACEMENT THERAPY (TRT) INFREQUENTLY USED IN HYPOGONADAL MEN (2015) (0)
FRII-13 HISTORY OF ANDROGEN DEPRIVATION APPROACHES FOR PROSTATE CANCER (2014) (0)
Challenges in the Treatment of Advanced Symptomatic Prostate Cancer Patients (2004) (0)
Advancing Treatment Strategies in Metastatic Castration-resistant Prostate Cancer: The Urologists Role. (2016) (0)
1583 AMERICAN UROLOGICAL ASSOCIATION SYMPTOM SCORE NOCTURIA QUESTION AS AN INDEPENDENT INDICATOR OF BPH IN A SCREENING POPULATION (2011) (0)
PD56-09 MICROBIOMES IN POST-DIGITAL RECTAL EXAM URINE SAMPLES ARE LINKED TO PROSTATE CANCER RISK (2021) (0)
FACTORS INFLUENCING METHOD OF INVESTIGATION OF AN ABNORMAL PSA IN THE PLCO TRIAL AND EFFECT ON CANCER DIAGNOSIS (2009) (0)
MP37-06 ANTIMICROBIAL RESISTANCE AND MICROBIAL PATTERNS WITHIN THE CHRONIC PROSTATITIS UROBIOME COMPARED TO ASYMPTOMATIC HEALTHY CONTROLS (2022) (0)
Re: Pharmacological erection program using prostaglandin E1. (1992) (0)
Prostate cancer: to screen or not to screen? (1997) (0)
Award Number: W81XWH-04-1-0858 TITLE: Magnetic Resonance Spectroscopy (MRS) of Prostatic Fluids for Early Detection of Prostate Cancer (2006) (0)
MP71-11 URINARY SYMPTOMS AND MEDICATIONS USED IN MEN ATTENDING A NATIONAL HEALTH SCREENING PROGRAM (2015) (0)
1928 REPEAT PSA AND DRE TESTING IN A PROSTATE CANCER SCREENING ENVIRONMENT (2012) (0)
FEASIBILITY OF THE PCA3 URINE TEST IN A COMMUNITY-BASED SCREENING SETTING (2009) (0)
Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial. (2018) (0)
Editorial Comment. (2018) (0)
Continuous release, solid depot, subcutaneous leuprolide acetate formulations to achieve and maintain castrate level serum testosterone levels below 20ng/dL in 4 open label, fixed dose studies. (2015) (0)
Cell cycle progression score to modify treatment decisions in prostate cancer: Results of an ongoing registry trial. (2014) (0)
Review Article ESTROGENS IN THE TREATMENT OF PROSTATE CANCER (1998) (0)
A 72-year-old man with prostate cancer. (2002) (0)
MP77-01 INDIVIDUAL, DNA-GUIDED, ANTIBACTERIAL PROPHYLAXIS PRIOR TO TRANSRECTAL PROSTATE BIOPSY BASED ON RESULTS OF NEXT GENERATION SEQUENCING (NGS) OF RECTAL SWABS IS A PROMISING TARGETED APPROACH TO PREVENT SEVERE URINARY TRACT INFECTION (2019) (0)
Editorial comment. (2012) (0)
MP29-02 EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS (2023) (0)
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations (2018) (0)
Update. Superficial bladder cancer. Diagnosis and treatment with intravesical agents (1996) (0)
MP09-06 DOES PROSTATE SPECIFIC ANTIGEN DENSITY IMPROVE DIAGNOSTIC ACCURACY OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN UNDERGOING TRANSPERINEAL MAPPING BIOPSY? (2020) (0)
The prostate cancer prevention trial: Current status. Discussion (2004) (0)
Abstract B131: Efficacy and safety of darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel in Black/African-American patients from the phase 3 ARASENS trial (2023) (0)
Prostate cancer update. (2003) (0)
The role of botulinum toxin a in the management of lower urinary tract symptoms (2008) (0)
Re: Pharmacological Erection Program Using Prostaglandin E1, by G. S. Gerber and L. A. Levine, J. Urol., 146: 786–789, 1991 (1992) (0)
MP50-20 IMPACT OF ABIRATERONE ACETATE IN PROSTATE SPECIFIC ANTIGEN TRIAL UPDATE: EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN AND RADIOGRAPHIC DISEASE PROGRESSION IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2016) (0)
The role of ultrasound in prostatic imaging. Introduction and overview. (1989) (0)
INCIDENCE OF PROSTATE CANCER WITHIN SKELETAL MUSCLE AT THE PROSTATE APEX IN MEN UNDERGOING RADICAL PROSTATECTOMY (2016) (0)
Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. (2020) (0)
PATTERN OF PSA CHANGE DURING SERIAL SCREENING IN THE PLCO CANCER SCREENING TRIAL AFFECTS PROSTATE CANCER RISK (2009) (0)
MP87-19 EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: THE RESULTS FROM IMPACT OF ABIRATERONE ACETATE IN PROSTATE-SPECIFIC ANTIGEN CORE STUDY (2015) (0)
MP37-18 LATE DOSING OF LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS AND TESTOSTERONE LEVELS >20NG/DL IN PROSTATE CANCER (2020) (0)
Editorial Commentary (2020) (0)
CCP Score Stratifies Risk for Prostate Cancer Patients at Biopsy: Initial Commercial Results (2014) (0)
Application and validation of registration framework for real-time atlas guided biopsy (2008) (0)
Legends in urology. (2008) (0)
Regional differences in cardiovascular status and events in prostate cancer patients treated with a gonadotrophin-releasing hormone agonist vs antagonist: Results of a pooled analysis. (2015) (0)
POD-04.06 The Effect of Increasing Doses of a Saw Palmetto Fruit Extract on Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Randomized Trial (2011) (0)
The Impact of Late LHRH Agonist Dosing on Testosterone Suppression in Prostate Cancer Patients: An Analysis of US Clinical Data. (2019) (0)
Review Article Role of Testosterone in Managing Advanced Prostate Cancer (2012) (0)
Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study. (2023) (0)
Should hormone treatment be started early in response to rising PSA levels (2007) (0)
Chemotherapeutic prevention studies of prostate cancer. Discussion (2004) (0)
A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma? (2009) (0)
2137 MINIMALLY INVASIVE 16G OPTICAL BIOPSY NEEDLE FOR PROSTATE CANCER DIAGNOSIS (2011) (0)
Comparison of biochemical progression rates after radical prostatectomy and radiotherapy for localized prostate cancer (2006) (0)
Chemoprevention and prostate cancer. (1997) (0)
Editorial Commentary (2019) (0)
Late administration of luteinizing hormone-releasing hormone agonists, the impact on testosterone (T) suppression, and frequency of T and PSA testing in prostate cancer in the real-world (2019) (0)
Reply by the authors. (2014) (0)
Being sensitive to the psychological needs of patients with prostate cancer. (1995) (0)
Transperineal Biopsy Technique (2016) (0)
Evaluation of prostate cancer risk in men with PSA < 1.5. (2018) (0)
ROUTINE SCREENING FOR CANCER OF THE PROSTATE. AUTHOR'S REPLY (1991) (0)
DETERMINANTS OF RADICAL PROSTATECTOMY IN THE PROSTATE, LUNG, COLORECTAL, OVARIAN (PLCO) CANCER SCREENING TRIAL (2008) (0)
MP29-01 RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS (2023) (0)
Chapter 31 - Radical Prostatectomy: The Retropublic Antegrade Approach (2003) (0)
635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels (2020) (0)
PREDICTORS OF THE ANDROGEN DEFICIENCY IN MEN (ADAM) SYNDROME IN A PROSTATE CANCER SCREENING POPULATION (2009) (0)
668: Pre Radiation PSA Predicts for Outcome of Adjuvant Radiation in SWOG 8794 (2006) (0)
1139 RELATIONSHIP BETWEEN SERUM TESTOSTERONE, BMI, FAT CONSUMPTION, AND EXERCISE (2012) (0)
Chapter 128 – Testis Tumor (2004) (0)
Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index. (2016) (0)
Effect of 3D automated prostate segmentation for ultrasound image guided repeat biopsy application (2008) (0)
MP48-02 FLUORESCENCE SPECTROSCOPY CAN INCREASE DIAGNOSTIC YIELD OF PROSTATE BIOPSIES (2015) (0)
MP60-08 PROSTATE HEALTH INDEX IS AN EFFECTIVE MARKER FOR RISK STRATIFICATION OF PROSTATE CANCER PATIENTS (2015) (0)
Surrogate Endpoint Biomarkers for Clinical Trials of Prostate Cancer Chemoprevention (1999) (0)
Recent advancements in the treatment of prostate cancer. (1985) (0)
Panel Discussion (1964) (0)
Pursuit of the renal mass. (1979) (0)
Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma. (2016) (0)
THE INCIDENCE AND CHARACTERIZATION OF THE METABOLIC SYNDROME IN A PROSTATE CANCER SCREENING POPULATION (2009) (0)
The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) > 1.5 Improves the Detection of Clinically Significant Cancers in Men Undergoing Transperineal Biopsy of the Prostate (2019) (0)
Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026. (2014) (0)
MP60-11 PERFORMANCE OF PROSTATIC SPECIFIC ANTIGEN DENSITY (PSAD) PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER (csPCa) IN BIOPSY NAIVE MEN, WITH A PRIOR NEGATIVE TRUS BIOPSY, OR LOW-GRADE CANCER (2021) (0)
1791: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Biopsy Rates and Cancer Characteristics of Initial (To) Screen (II) (2004) (0)
Editorial Comment. (2019) (0)
Epigenetic profiling of prostate cancer tissue to identify men with high-risk disease. (2014) (0)
Vol. 35, 1999 (1999) (0)
1699: The Observed Effect of Flomax Intake on Sexual Health in Men with Lower Urinary Tract Symptoms. Analysis from the Prostate Cancer Awareness Week (PCAW) (2005) (0)
MP35-11 COMPARATIVE ANALYSIS OF THE MICROBIOME OF CHRONIC PROSTATITIS, ACUTE CYSTITIS AND ASYMPTOMATIC HEALTHY SUBJECTS: THE KEY TO INTERPRETATION OF NEXT GENERATION SEQUENCING URINE REPORTS (2021) (0)
Author ' s Accepted Manuscript Impact of the CCP test on physician and patient treatment selection for localized prostate cancer (2015) (0)
Subject Index Vol. 35, 1999 (1999) (0)
PSA levels of >1.5-4 ng/mL in a men’s health evaluation as a method for informed decision making. (2015) (0)
Major adverse cardiovascular event risk following androgen deprivation therapy initiation by cardiovascular history (2022) (0)
Bridging the Treatment Gaps in the Management of Hypogonadism (2007) (0)
573 FACTORS INFLUENCING PROSTATE CANCER MORTALITY IN THE PLCO TRIAL (2010) (0)
1737 COMPARISON OF THE AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX WITH A SHORT VERSION, UWIN, IN A CLINICAL PHYTOTHERAPY TRIAL (2012) (0)
Prostate cancer in a man with multiple previous cancers. (2007) (0)
Benign and malignant prostatic diseases. (1991) (0)
MP73-16 SOLID DEPOT, CONTINUOUS RELEASE, SUBCUTANEOUS LEUPROLIDE ACETATE FORMULATIONS LASTING 1-6 MONTHS ACHIEVE AND MAINTAIN SERUM TESTOSTERONE LEVELS BELOW 20NG/DL IN 4 OPEN LABEL, FIXED DOSE STUDIES (2015) (0)
MP25-01 THE URINARY MICROBIOME OF HEALTHY ASYMPTOMATIC MEN AND WOMEN: A REFERENCE FOR INTERPRETATION OF NEXT GENERATION SEQUENCING URINE ANALYSES IN SYMPTOMATIC PATIENTS (2021) (0)
S031) Racial Disparities in Proton Beam Therapy Utilization in the United States (2017) (0)
Impact of testosterone levels and treatment on aging men’s health: should we worry? (2005) (0)
1361: A Modified American Urological Association (AUA) Symptom Score (2006) (0)
1844 ASSOCIATION OF STATIN USE TO SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN A SCREENING POPULATION (2010) (0)
Abstract LB-212: IMAAGEN study biomarker analysis in patients with long term response to abiraterone acetate with prednisone for non-metastatic castrate resistant prostate cancer (2018) (0)
Management of Prostate Cancer: A European-American Encounter, International Symposium, Munich, November 1996 (1997) (0)
PD01-02 COMPARATIVE ANALYSIS OF THE MICROBIOME OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME, CYSTITIS AND ASYMPTOMATIC HEALTHY CONTROLS: THE KEY TO INTERPRETATION OF NEXT GENERATION SEQUENCING URINE REPORTS (2021) (0)
Highlights from the 20th International Prostate Cancer Update (2010) (0)
Do tumor characteristics and prognostic factors differ between subsequent rounds of PSA screening for prostate cancer? (2007) (0)
MP57-07 TRANSPERINEAL PROSTATE MAPPING BIOPSY CORRECTLY IDENTIFIES CANDIDATES FOR RADICAL PROSTATECTOMY (2016) (0)
CMAR_A_227583 5667..5676 (2020) (0)
MP45-04 SELECTMDX URINE TEST DIAGNOSE MEN WITH HIGH-GRADE PROSTATE CANCER (2022) (0)
Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921. (2017) (0)
Editorial Comment. (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Elward David Crawford?

Elward David Crawford is affiliated with the following schools:

Elward David Crawford's Academic­Influence.com Rankings

Elward David Crawford's Degrees

Why Is Elward David Crawford Influential?

Elward David Crawford's Published Works

Published Works

What Schools Are Affiliated With Elward David Crawford?

Elward David Crawford's AcademicInfluence.com Rankings